+1-646-568-9980, +44-203-287-6050
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
global hypertension drug market

Global Hypertension Drug Market, [By Hypertension type (Primary Hypertension, Secondary Hypertension), By Therapy Type (Beta Blockers Vasodilators, Calcium Channel Blockers, Angiotensin Converting Enzymes, Diuretics, Angiotensin Receptor Blockers, Renin Inhibitors)]; and Geography - Trend, Analysis and Forecast till 2025

Published: Jul 2018
Pages: 0
Format: PDF
Report ID: PM1331
License and Pricing
Buy Now Inquire Before Buying

Report Summary

The Global Hypertension Drug Market Size is observed to gain traction owing to various factors including rise in population count suffering from high blood pressure.

Hypertension is defined as a condition where arteries in the heart has continuously elevated pressure. It is also referred to as high blood pressure (HBP). According to American Heart Association 2017, hypertension is defined as a condition of blood pressure higher than 130 and 80 millimetres of mercury (mmHg). The measurement of blood pressure is expressed in terms namely; systolic pressure and diastolic pressure. An individual suffering from hypertension for long time has major risk of heart stroke, heart failure, atrial fibrillation, dementia, and vision loss.

Blood pressure is further categorized into primary high blood pressure and secondary high blood pressure. Primary high blood pressure holds the largest market share owing to its increasing number of cases due to changing lifestyle and various genetic factors. Primary hypertension is majorly influenced by the factors such as; excess salt in the diet, excess body weight, excessive intake of alcohol, and active or passive smoking. However, secondary high blood pressure accounts for a smaller market share. Secondary high blood pressures causes are easily identified that include chronic kidney disease, endocrine disorder, excess use of birth controlling pills.

According to Centres for Disease Control and Prevention (CDC), high blood pressure or hypertension is the major cause of heart disease, and heart stroke in the U.S. Moreover, approximately 32% of adults have high blood pressure  in the U.S. which accounts for the ratio of 1 in every 3 adults. Additionally, high blood pressure is becoming one of the leading causes of death in North America during recent past.

Rising demand for effective treatment of high blood pressure and high number of drug patent expiration will support the growth of global market.

The global market is primarily driven by the factors such as growing number of patients suffering from high blood pressures globally.  Hypertension majorly causes cardiovascular diseases like heart stroke, and heart failure which cause higher number of deaths. As per 2013 WHO reports, approximately 45% of heart related deaths were due to hypertension. Moreover, the rising preference for the sedentary lifestyle in the developing countries is another factor contributing to the growth of hypertension cases.

Increasing expiry of patented drug has created lucrative opportunities in the existing market. In addition, increasing number and availability of generic drugs shall also boost the growth of this market. Also, the rising interest of local governments and their increased focus on patient assistance to propel the global market.  

However, relative side effects by the use of hypertension drug and availability of alternative therapies in the developing countries can hinder growth of hypertension drug market in the near future.

Global hypertension drug Market Taxonomy

The global hypertension drug market is segmented on the basis of hypertension type, therapy type, and geography.

On the basis of hypertension type, global hypertension drug market is segmented into:

  • Primary High Blood Pressure
  • Secondary High Blood Pressure

On the basis of therapy type, global hypertension drug market is segmented into:

  • Beta Blockers Vasodilators
  • Calcium Channel Blockers
  • Angiotensin Converting Enzyme
  • Diuretics
  • Angiotensin Receptor Blockers
  • Renin Inhibitors.

Geographically, the global hypertension drug market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Increased prevalence of hypertension and effective development of treatments to lead the global hypertension drug in North America.

Geographically, the market to be segmented as North America, Europe, Asia Pacific, Latin America & Middle East and Africa. Among the region, North America is expected to dominate this market during the forecast period. The North American region holds major share of this market owing to rising number of patients suffering from hypertension, and is one of the leading cause of death in this region. Also, increasing awareness for the use of alternative drugs, and increasing geriatric population in North America are factors enhancing the hypertension drug market in the near future.

However, Asia Pacific is expected to witness fast market growth during the forecast period. Increasing number of patients with hypertension, and rising awareness for the use of various drugs and therapies are the major factor anticipated to govern the global market during upcoming years.

Key players in the global hypertension drug market are:

  • Pfizer Inc.
  • Lupin Limited
  • Novartis AG
  • Ranbaxy Laboratories limited
  • AstraZenca plc.
  • Johnson & Johnson Ltd.
  • Boehringer Ingelheim
  • Merck & Company
  • Sanofi S.A.
  • Daiichi-Sankyo
  • Sun Pharmaceuticals LLC
Key Take-Away